6UQR

Complex of IgE and Ligelizumab

Summary for 6UQR

Entry DOI	10.2210/pdb6uqr/pdb
Descriptor	Ligelizumab, IgE, alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... (4 entities in total)
Functional Keywords	anti-ige antibody, complex, monoclonal, immune system
Biological source	Homo sapiens (Human) More
Total number of polymer chains	4
Total formula weight	114692.55
Authors	Tarchevskaya, S.S.,Kleinboelting, S.,Jardetzky, T.S. (deposition date: 2019-10-21, release date: 2019-12-04, Last modification date: 2023-10-11)
Primary citation	Gasser, P.,Tarchevskaya, S.S.,Guntern, P.,Brigger, D.,Ruppli, R.,Zbaren, N.,Kleinboelting, S.,Heusser, C.,Jardetzky, T.S.,Eggel, A. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. Nat Commun, 11:165-165, 2020 Cited by PubMed: 31913280 DOI: 10.1038/s41467-019-13815-w PDB entries with the same primary citation
Experimental method	X-RAY DIFFRACTION (3.65029109708 Å)

Structure validation